161,272 Shares in Catalyst Pharmaceuticals, Inc. $CPRX Acquired by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 161,272 shares of the biopharmaceutical company's stock, valued at approximately $3,911,000. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.13% of Catalyst Pharmaceuticals as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Park Square Financial Group LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter valued at $29,000. Sound Income Strategies LLC bought a new position in Catalyst Pharmaceuticals during the 1st quarter worth $64,000. GAMMA Investing LLC raised its position in Catalyst Pharmaceuticals by 26.2% during the 1st quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock worth $68,000 after purchasing an additional 579 shares during the last quarter. Quarry LP bought a new position in Catalyst Pharmaceuticals during the 4th quarter worth $104,000. Finally, New Vernon Capital Holdings II LLC bought a new position in Catalyst Pharmaceuticals during the 4th quarter worth $122,000. Institutional investors and hedge funds own 79.22% of the company's stock.

Catalyst Pharmaceuticals Stock Up 0.2%

CPRX stock traded up $0.04 during mid-day trading on Monday, reaching $20.27. 483,025 shares of the company traded hands, compared to its average volume of 1,315,118. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $19.00 and a fifty-two week high of $26.58. The firm's 50 day moving average price is $21.75 and its 200 day moving average price is $22.69. The stock has a market cap of $2.48 billion, a price-to-earnings ratio of 12.29, a P/E/G ratio of 0.82 and a beta of 0.70.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on CPRX. Wall Street Zen lowered Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Saturday, August 9th. Cantor Fitzgerald raised Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, June 5th. One analyst has rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $33.20.

Insider Activity at Catalyst Pharmaceuticals

In related news, insider Preethi Sundaram sold 1,600 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $26.42, for a total value of $42,272.00. Following the sale, the insider owned 41,081 shares of the company's stock, valued at approximately $1,085,360.02. The trade was a 3.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 10.40% of the company's stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.